Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ: VCYT ) with a Buy and raises the price target from $45 to $65.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.